NO3009428T3 - - Google Patents

Info

Publication number
NO3009428T3
NO3009428T3 NO15189570A NO15189570A NO3009428T3 NO 3009428 T3 NO3009428 T3 NO 3009428T3 NO 15189570 A NO15189570 A NO 15189570A NO 15189570 A NO15189570 A NO 15189570A NO 3009428 T3 NO3009428 T3 NO 3009428T3
Authority
NO
Norway
Application number
NO15189570A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3009428(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3009428T3 publication Critical patent/NO3009428T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO15189570A 2009-05-08 2010-05-06 NO3009428T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009113936 2009-05-08
EP10772177.1A EP2428508B9 (fr) 2009-05-08 2010-05-06 Composé de carboxamide hétérocyclique diamino

Publications (1)

Publication Number Publication Date
NO3009428T3 true NO3009428T3 (fr) 2018-07-21

Family

ID=43050157

Family Applications (2)

Application Number Title Priority Date Filing Date
NO15189570A NO3009428T3 (fr) 2009-05-08 2010-05-06
NO2020001C NO2020001I1 (no) 2009-05-08 2020-01-16 Gilteritinib eller et salt derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2020001C NO2020001I1 (no) 2009-05-08 2020-01-16 Gilteritinib eller et salt derav

Country Status (29)

Country Link
US (2) US8969336B2 (fr)
EP (2) EP3009428B1 (fr)
JP (1) JP5364159B2 (fr)
KR (1) KR101614572B1 (fr)
CN (1) CN102421761B (fr)
AU (1) AU2010245545B2 (fr)
BR (1) BRPI1011838B8 (fr)
CA (1) CA2760061C (fr)
CY (3) CY1117546T1 (fr)
DK (2) DK2428508T3 (fr)
ES (2) ES2559230T3 (fr)
FR (1) FR20C1003I2 (fr)
HK (1) HK1219105A1 (fr)
HR (2) HRP20151435T8 (fr)
HU (3) HUE038515T2 (fr)
IL (1) IL216132A (fr)
LT (2) LT3009428T (fr)
LU (1) LUC00147I2 (fr)
MX (1) MX2011011875A (fr)
NL (1) NL301028I2 (fr)
NO (2) NO3009428T3 (fr)
PL (2) PL3009428T3 (fr)
PT (2) PT3009428T (fr)
RS (2) RS57045B1 (fr)
SI (2) SI3009428T1 (fr)
SM (1) SMT201600075B (fr)
TW (1) TWI484961B (fr)
WO (1) WO2010128659A1 (fr)
ZA (1) ZA201108642B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102083800A (zh) 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR102132405B1 (ko) 2010-05-20 2020-07-09 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
WO2012021444A1 (fr) 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Sel de bésylate d'un inhibiteur de btk
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
WO2012061299A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétérocycliques et leurs utilisations
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US20130317029A1 (en) * 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
EP3564261A1 (fr) 2011-08-23 2019-11-06 Foundation Medicine, Inc. Molécules de fusion kif5b-ret et leurs utilisations
EP2770830A4 (fr) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)
SG11201402570QA (en) * 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
US9085540B2 (en) 2012-01-17 2015-07-21 Astellas Pharma Inc. Pyrazinecarboxamide compound
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
EP2825041B1 (fr) 2012-03-15 2021-04-21 Celgene CAR LLC Formes solides d'un inhibiteur de kinases du récepteur du facteur de croissance épidermique
US9206166B2 (en) * 2012-11-06 2015-12-08 SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES Certain protein kinase inhibitors
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP2016509012A (ja) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｅｒｋ阻害剤およびそれらの使用
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN104262328B (zh) * 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
SG11201602595TA (en) 2013-10-11 2016-04-28 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
TR201911140T4 (tr) 2013-10-21 2019-08-21 Merck Patent Gmbh Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
CA2932609A1 (fr) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015106025A1 (fr) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Benzoxazine substituée et composés associés
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
RS60150B1 (sr) * 2014-02-04 2020-05-29 Astellas Pharma Inc Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenje karboksamida kao aktivni sastojak
CN104016977B (zh) * 2014-06-13 2016-06-22 山东大学 一种取代噻二嗪二酮类衍生物及其制备方法与应用
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
JP6762940B2 (ja) 2014-12-16 2020-09-30 シグナル ファーマシューティカルズ，エルエルシー ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの製剤
WO2016100308A1 (fr) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Procédés de mesure de l'inhibition de la kinase à terminaison n c-jun dans la peau
WO2016123291A1 (fr) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
CN107847500B (zh) * 2015-07-03 2021-08-10 安斯泰来制药株式会社 稳定的口服给药用药物组合物
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
AU2016297784B2 (en) 2015-07-24 2020-12-24 Celgene Corporation Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3372231B1 (fr) * 2015-11-04 2021-09-15 Astellas Pharma Inc. Composition pharmaceutique pour l'immunothérapie anticancéreuse et/ou pour l'immunostimulation, contenant comme principe actif un composé diamino carboxamide hétérocyclique
WO2017146236A1 (fr) 2016-02-26 2017-08-31 小野薬品工業株式会社 Médicament pour le traitement du cancer caractérisé par l'administration d'une association d'un inhibiteur de l'axl et d'un inhibiteur de point de contrôle immunitaire
CN106083821B (zh) * 2016-06-22 2019-01-11 上海皓元生物医药科技有限公司 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CA3049136C (fr) 2017-01-18 2022-06-14 Array Biopharma Inc. Composes de pyrazolo[1,5-a]pyrazine substitues utilises en tant qu'inhibiteurs de la kinase ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020519665A (ja) 2017-05-17 2020-07-02 アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） オピオイドによる痛みの処置を改善する為のｆｌｔ３阻害剤
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
EP3695839A4 (fr) 2017-10-13 2021-07-14 ONO Pharmaceutical Co., Ltd. Agent thérapeutique pour cancers solides, qui contient un inhibiteur d'axl en tant que principe actif
CA3087972C (fr) 2018-01-18 2023-01-10 Array Biopharma Inc. Composes de pyrazolyl[4,3-c]pyridine substitues utilises en tant qu'inhibiteurs de la kinase ret
CA3087578C (fr) 2018-01-18 2023-08-08 Array Biopharma Inc. Composes de pyrazolo[3,4-d]pyrimidine substitues utilises en tant qu'inhibiteurs de la kinase ret
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
JP7492742B2 (ja) * 2018-03-28 2024-05-30 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ジアミノ複素環式カルボキサミド化合物、該化合物を含む組成物およびその使用
WO2020055672A1 (fr) 2018-09-10 2020-03-19 Array Biopharma Inc. Composés hétérocycliques condensés comme inhibiteurs de kinases ret
CN112839930B (zh) 2018-09-30 2022-03-15 南京明德新药研发有限公司 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
EP3870579A4 (fr) * 2018-10-22 2022-10-19 Alumis Inc. Inhibiteurs de tyk2 et leurs utilisations
KR20210139317A (ko) 2019-03-13 2021-11-22 오츠카 세이야쿠 가부시키가이샤 2급 아민을 함유하는 화합물의 아민 부분에 중수소 저급 알킬을 도입하는 방법
KR20210148252A (ko) 2019-04-03 2021-12-07 아스텔라스세이야쿠 가부시키가이샤 의약 조성물
US20230141887A1 (en) * 2020-03-30 2023-05-11 Medshine Discovery Inc. Crystal form of diazaspiropyran compound
CN111423387B (zh) * 2020-05-11 2022-03-08 苏州康纯医药科技有限公司 一种Gilteritinib关键中间体的制备方法
CA3179395A1 (fr) * 2020-06-01 2021-12-09 Yuli Xie Nouveau compose de pyrazine
WO2022009235A1 (fr) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Procédé de préparation de fumarate de giltéritinib
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN112225703B (zh) * 2020-09-28 2022-03-11 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
WO2022078305A1 (fr) * 2020-10-12 2022-04-21 四川海思科制药有限公司 Dérivé hétérocyclique et son application médicale
WO2023027966A1 (fr) * 2021-08-24 2023-03-02 Biomea Fusion, Inc. Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
WO2023129667A1 (fr) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Composés pyrazines utilisés comme inhibiteurs de flt3
WO2023178094A2 (fr) * 2022-03-14 2023-09-21 Purdue Research Foundation Inhibiteur de tyrosine kinase de la rate, composition et procédés d'utilisation
WO2023225005A1 (fr) * 2022-05-17 2023-11-23 Biomea Fusion, Inc. Polythérapie à base de flt3 pour le cancer et compositions associées
CN115124590A (zh) * 2022-07-05 2022-09-30 武汉大学中南医院 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017898T2 (de) 1999-06-09 2006-01-12 Yamanouchi Pharmaceutical Co., Ltd. Neuartige heterocyclische carboxamidderivate
WO2000076980A1 (fr) * 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques azotes ou leurs sels
CN1665789A (zh) 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
WO2008016660A2 (fr) * 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Composés de traitement de la leucémie
US20080070930A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
EP1914240B1 (fr) 2006-10-11 2009-12-02 Astellas Pharma Inc. Gène de fusion EML4-ALK
CL2007003049A1 (es) 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
CA2673184A1 (fr) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh Nouveaux composes
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CA2693594A1 (fr) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Pyrimidinediamines substituees par des amines cycliques utilisees en tant qu'inhibiteurs de la pkc
WO2009020990A1 (fr) 2007-08-08 2009-02-12 Smithkline Beecham Corporation Dérivés de 2-[(2-{phénylamino}-1h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide en tant qu'inhibiteur d'igf-1r pour le traitement du cancer
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
JP5501234B2 (ja) 2007-09-28 2014-05-21 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピロロ−ピリミジン誘導体、これらの調製方法およびキナーゼ阻害剤としてのこれらの使用
US20090270418A1 (en) 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
MX2010011069A (es) 2008-04-07 2010-11-12 Irm Llc Compuestos y composiciones como inhibidores de cinasa.
BRPI0911228A2 (pt) 2008-04-07 2017-05-30 Irm Llc compostos e composições como inibidores de proteínas quinase
EP2323993B1 (fr) * 2008-04-16 2015-06-03 Portola Pharmaceuticals, Inc. 2,6-diamino- pyrimidin- 5-yl-carboxamides comme inhibiteurs de la syk ou jak protéine kinase
CN102066340B (zh) 2008-04-16 2014-05-14 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体

Also Published As

Publication number Publication date
HRP20151435T1 (hr) 2016-03-25
SI2428508T1 (sl) 2016-04-29
JPWO2010128659A1 (ja) 2012-11-01
CN102421761B (zh) 2014-06-18
FR20C1003I1 (fr) 2020-03-20
HK1219105A1 (zh) 2017-03-24
NL301028I2 (nl) 2020-04-15
TW201105326A (en) 2011-02-16
EP3009428B1 (fr) 2018-02-21
WO2010128659A1 (fr) 2010-11-11
KR101614572B1 (ko) 2016-04-21
CA2760061A1 (fr) 2010-11-11
FR20C1003I2 (fr) 2020-12-04
US20140371196A1 (en) 2014-12-18
US9487491B2 (en) 2016-11-08
LUC00147I2 (fr) 2021-02-12
CN102421761A (zh) 2012-04-18
EP2428508A1 (fr) 2012-03-14
AU2010245545B2 (en) 2014-09-11
CY1117546T1 (el) 2017-04-26
CY2020004I1 (el) 2020-05-29
ES2559230T3 (es) 2016-02-11
SMT201600075B (it) 2016-04-29
RU2526253C2 (ru) 2014-08-20
RS54552B1 (en) 2016-06-30
DK2428508T3 (en) 2016-02-01
AU2010245545A1 (en) 2011-11-03
BRPI1011838A2 (pt) 2018-02-06
HRP20151435T8 (hr) 2016-07-01
ES2667706T3 (es) 2018-05-14
IL216132A0 (en) 2012-01-31
HUE038515T2 (hu) 2018-10-29
DK3009428T3 (en) 2018-03-26
MX2011011875A (es) 2011-12-08
LTC2428508I2 (lt) 2020-12-28
HUS000511I2 (hu) 2021-03-29
HUS2000005I1 (hu) 2020-03-30
LTPA2020002I1 (lt) 2020-02-10
EP2428508B1 (fr) 2015-12-16
PT2428508E (pt) 2016-02-29
KR20120007523A (ko) 2012-01-20
CY1120367T1 (el) 2019-07-10
JP5364159B2 (ja) 2013-12-11
US8969336B2 (en) 2015-03-03
LUC00147I1 (fr) 2020-02-10
CY2020004I2 (el) 2020-05-29
BRPI1011838B8 (pt) 2021-05-25
RS57045B1 (sr) 2018-05-31
IL216132A (en) 2015-10-29
PL3009428T3 (pl) 2018-07-31
US20120040968A1 (en) 2012-02-16
HRP20180368T1 (hr) 2018-04-06
EP2428508B9 (fr) 2016-04-20
TWI484961B (zh) 2015-05-21
CA2760061C (fr) 2017-02-28
ZA201108642B (en) 2013-02-27
SI3009428T1 (en) 2018-04-30
BRPI1011838B1 (pt) 2021-03-16
HUE026647T2 (en) 2016-07-28
PL2428508T3 (pl) 2016-05-31
LT3009428T (lt) 2018-04-10
EP2428508A4 (fr) 2012-11-28
NL301028I1 (nl) 2020-01-22
NO2020001I1 (no) 2020-01-16
EP3009428A1 (fr) 2016-04-20
RU2011149799A (ru) 2013-06-20
PT3009428T (pt) 2018-04-02

Similar Documents

Publication Publication Date Title
LUC00147I2 (fr)
BR112012012396A2 (fr)
BR112012008267A2 (fr)
BR112012003062A2 (fr)
BR112012008195A2 (fr)
BR112012003080A2 (fr)
BR122021004633A2 (fr)
BR122017024704A2 (fr)
BR112012012487A2 (fr)
BR112012000665A2 (fr)
BR112012003853A2 (fr)
BR112012012080A2 (fr)
BR112012009797A2 (fr)
BR112012009446A2 (fr)
BR112012009703A2 (fr)
BR112012010357A2 (fr)
BR112012007656A2 (fr)
BR122019005883A2 (fr)
BR112012002627A2 (fr)
BR112012001263A2 (fr)
BR112012007672A2 (fr)
BR112012007654A2 (fr)
BR112012005951A2 (fr)
BR122017013721A2 (fr)
BR112012009404A2 (fr)